Publication
Mission impossible? Teresa Ribera’s mission letter and the future of EU merger review
Executive Vice President Vestager’s momentous tenure as Commissioner responsible for EU competition policy is nearing its end.
Global | Publication | November 2018
Since the global financial crisis, there has been an ever-increasing focus globally on holding those in senior positions within regulated financial institutions accountable for their actions. This phenomenon has forced firms to adapt and prepare their practice for the implementation of new and more scrupulous obligations.
Our Individual accountability hub has been created on the NRF Institute to provide a comprehensive understanding of the new expectations for anyone preparing for, and needing to comply with, individual accountability obligations across the globe.
Also available via the hub is our SMCR Toolkit, a subscription-only, cost-effective service providing access to all of the key documents that firms need to implement the regime within their business.
To request access to ‘Individual accountability hub,’ please register to join NRF Institute.
Registration indicates acceptance of the terms and conditions which include important information about how our product will be delivered.
Members of NRF Institute can access a range of premium content including knowledge hubs and cross-border guides.
Publication
Executive Vice President Vestager’s momentous tenure as Commissioner responsible for EU competition policy is nearing its end.
Publication
On 10 October 2024, the UK government published its long awaited response (the Response) to its January 2024 consultation on “Designing a policy framework to enable investment in long duration electricity storage” (the Consultation).
Publication
Miranda Cole, Julien Haverals and Emma Clarke of our Brussels/ London offices are the authors of a chapter on procedural issues in merger control that has been published in the third edition of the Global Competition Review’s The Guide to Life Sciences. This covers a number of significant procedural developments that have affected merger review of life sciences transactions.
Subscribe and stay up to date with the latest legal news, information and events . . .
© Norton Rose Fulbright LLP 2023